

A1  
cont'd

of the matrix metalloproteinases selected from the group consisting of neutrophil collagenase (MMP-8), aggrecanase, hADAMTS1, and gelatinase A (MMP-2), wherein the disorder is a degenerative joint disorder, connective tissue disorder, wound healing disturbance, periodontal disorder, disorder of the locomotor system, or disturbance of bone metabolism.

A2

(Amended) The method of claim 1, wherein the disorder is osteoarthroses, spondyloses, chondrolysis, collagenoses, an inflammatory disorder, immunological or metabolism-related acute or chronic arthritides, arthropathies, or myalgias.

Please add the following claims:

- A3
11. (Added) A method of reducing the activity of at least one of the matrix metalloproteinases selected from the group consisting of neutrophil collagenase (MMP-8), aggrecanase, hADAMTS1, and gelatinase A (MMP-2) in a subject, comprising administering to the subject a therapeutically effective amount of enoxaparin.
  12. (Added) The method of claim 11, wherein the subject has a degenerative joint disorder, connective tissue disorder, wound healing disturbance, periodontal disorder, disorder of the locomotor system, or disturbance of bone metabolism.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

- A<sup>3</sup>  
concl'd
13. (Added) The method of claim 12, wherein the disorder is osteoarthroses, spondyloses, chondrolysis, collagenoses, an inflammatory disorder, immunological or metabolism-related acute or chronic arthritides, arthropathies, or myalgias.
  14. (Added) The method of claim 11, wherein the enoxaparin is administered by subcutaneous, intraarticular, intraperitoneal, or intravenous injection.
  15. (Added) The method of claim 14, wherein the enoxaparin is administered by intraarticular injection.
  16. (Added) The method of claim 11, wherein the dose of enoxaparin is from about 5 µg to about 200 mg.
  17. (Added) The method of claim 11, wherein the dose of enoxaparin is from about 10 µg to about 40 mg.
  18. (Added) The method of claim 1, wherein the enoxaparin is administered rectally, orally, inhalationally, or transdermally.

## REMARKS

### I. Status of the Claims

Claims 1-10 are pending in this application. The Office has withdrawn claims 9 and 10, as being directed to a non-elected invention, and has rejected claims 1-8. With entry of this amendment, Applicants have amended claims 1 and 3; added claims 11-18; and canceled claims 2, 9, and 10, without prejudice to or disclaimer of the subject matter recited therein. Support for the amended